About GeneDx
GeneDx focuses on clinical genomics and rare disease diagnostics through genetic testing, analyzing DNA to identify mutations linked to health conditions. They have sequenced over 300,000 clinical patient exomes, using samples from cheek swabs and blood, with results analyzed by experts and reported to healthcare providers. GeneDx stands out by offering rapid testing services, delivering results in as little as seven days, which is crucial for timely diagnoses. Their goal is to lead in clinical genomics by providing fast and reliable genetic testing to improve the management of genetic conditions.
Gaithersburg, MarylandHeadquarters
2000Year Founded
$1,414MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
501-1,000Employees
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Unlimited Paid Time Off
401(k) Retirement Plan
Employee Discounts
Voluntary benefits
Risks
Competitors' AI advancements could outpace GeneDx's current genomic tools.
Regulatory changes in data privacy may impact GeneDx's operations.
Financial risks exist if biopharma partnerships do not yield expected results.
Differentiation
GeneDx combines genomic expertise with AI for precise clinical data interpretation.
Centrellis platform synthesizes clinical and genomic data for advanced diagnostics.
GeneDx Discover tool accelerates drug discovery with vast genetic data access.
Upsides
GeneDx's rapid exome sequencing offers critical diagnoses in as little as seven days.
Partnerships with biopharma enhance drug discovery and expand market opportunities.
Patient Access Program increases exome testing access for pediatric epilepsy patients.
Funding
Total raised$1.41 B
Latest valuation$623.00 M
StageIPO
DEBT
9/30/2023$75
ACQUISITION
12/31/2021$623
$623.00 M